By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ViroPharma Incorporated 

730 Stockton Drive

Exton  Pennsylvania  19341  U.S.A.
Phone: 610-458-7300 Fax: 610-458-7380


ViroPharma Incorporated is a global biotechnology company dedicated to developing and commercializing products that help address dangerous, potentially life-threatening conditions such as hereditary angioedema (HAE), seizures in children and adolescents, and adrenal insufficiency. ViroPharma is headquartered in Exton, PA and has operations throughout Europe.

ViroPharma’s core focus is on providing patients and physicians new therapeutic alternatives for today’s great unmet medical needs. ViroPharma has gained commercial approval for three important therapeutics in the United States or Europe, with several others in clinical development. For example, our product Cinryze (R) (C1 Esterase Inhibitor (human)) is indicated in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. In Europe, it is indicated for prophylaxis against HAE attacks, pre-procedure prophylaxis, and acute treatment of attacks of HAE in children and adolescents with HAE.

HAE is a rare inherited disorder which is characterized by painful swelling that can appear in various parts of the body. It most commonly affects the hands, feet, face, abdomen, urogenital tract, and upper respiratory tract. The inflammation can be disfiguring, debilitating, or in the case of laryngeal attack, life-threatening. If left untreated, HAE can result in a mortality rate as high as 40%, primarily due to upper airway obstruction or suffocation in undiagnosed patients.

ViroPharma is engaged in life-cycle management work with Cinryze on additional indications, formulations, and territories. In addition, our preclinical and clinical pipeline includes non-toxigenic C. difficile (NTCD), targeting prevention of recurrence of disease following therapy for acute C. difficile infection (CDI), a phase 1 compound targeting a rare disease called Friedreich's ataxia, several clinical and investigator initiated studies of C1 esterase inhibitor in diseases mediated by the complement cascade, and our Phase 2 agent called maribavir, targeting transplant-associated cytomegalovirus (CMV) infection.

Through the success ViroPharma’s products and our management team’s savvy business model, the company’s is well positioned financially to continue to add new products that will provide hope to physicians treating patients with unmet medical needs.

ViroPharma is an equal opportunity employer and promotes diversity throughout its organization. A strong foundation of shared values among the people of ViroPharma, brought together with a clear and common purpose, has contributed to the culture of ViroPharma. The company is seeking individuals with the skills and passion for results to join the ViroPharma team as part of the catalyst to future success. In addition to a rewarding work environment emphasizing teamwork, commitment and communication, ViroPharma provides competitive salaries, medical/dental benefits, a 401(k) plan and stock options.

Please visit ViroPharma’s Online Recruitment Center to complete a profile and apply.

Key Statistics

Ownership: Public

Web Site: ViroPharma
Employees: 340
Symbol: VPHM


Company News
FTC Sues Shire (SHPG) ViroPharma (VPHM) for Using Illegal Tactics to Block Generic Competition 2/8/2017 6:39:27 AM
$4.2 Billion Deal Gives ViroPharma Incorporated (VPHM) Execs Huge Paydays 2/7/2014 6:48:15 AM
Shire plc Extends Tender Offer For ViroPharma Incorporated (VPHM), Acceptances Up To 76 Percent 12/27/2013 6:33:07 AM
Hart-Scott-Rodino Waiting Period Expires for Shire's Acquisition Of ViroPharma Incorporated (VPHM) 12/11/2013 9:27:53 AM
Shire plc's Acquisition Of ViroPharma Incorporated (VPHM) Will Add $831 Million In Revenue By 2018, Says GlobalData 11/18/2013 11:33:46 AM
ViroPharma Incorporated (VPHM) Release: Analysis Of Pivotal Study Data Showed Routine Prevention Of Hereditary Angioedema (HAE) Attacks With Cinryze® (C1 Esterase Inhibitor [Human]) Resulted In Improved Health-Related Quality Of Life Outcomes Compared To Acute Therapy With C1 Inhibitor While On Placebo 11/12/2013 12:04:18 PM
Shire To Pay $4.2 Billion For Rare Disease Firm ViroPharma Incorporated (VPHM) 11/11/2013 7:11:38 AM
ViroPharma Incorporated (VPHM) Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting 11/7/2013 6:11:45 AM
ViroPharma Incorporated (VPHM) Reports Third Quarter 2013 Financial Results 10/31/2013 7:39:44 AM
ViroPharma Incorporated (VPHM) to Release 2013 Third Quarter Financial Results on October 31, 2013 10/28/2013 10:43:10 AM